METHAZOLAMIDE
Methazolamide is a carbonic anhydrase inhibitor reducing aqueous humor production for glaucoma therapy. Side effects include electrolyte imbalance, tingling, fatigue, and metabolic acidosis.
About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of Action
METHAZOLAMIDE (ID 26681) displays a broad and multi‑axis biochemical interaction profile characterised by modulation of enzymatic networks, receptor‑mediated signalling, intracellular ion regulation, mitochondrial bioenergetics and transcriptional pathway governance. Its structural features suggest interactions with catalytic and regulatory proteins, leading to changes in phosphorylation cycles, metabolic flux, mitochondrial redox balance, calcium‑signalling behaviour and stress‑response activation. Depending on cellular environment and concentration, the compound may act as an activator, inhibitor or regulatory modulator.
Benefits and Advantages
This compound supports a wide range of research applications, including:
- Receptor–ligand affinity profiling and binding‑site mapping
- Enzyme‑cascade modelling and catalytic‑domain interaction studies
- Mitochondrial‑function assays, oxidative‑stress evaluation and metabolic‑flux tracking
- Transcriptomic, proteomic and metabolomic investigation for pathway mapping
- Apoptosis / autophagy pathway research and cellular‑stress modelling
- High‑resolution mechanism‑of‑action studies and SAR exploration
Side Effects and Risks
Potential risks include oxidative imbalance, mitochondrial overload, ion‑channel dysregulation, receptor cross‑talk, cytoskeletal disruption and dose‑dependent cytotoxicity. At elevated exposure levels, the compound may induce apoptosis, autophagy, inflammatory signalling, metabolic reprogramming or transcriptional instability. Proper laboratory controls and strict biosafety procedures are required for handling.
Datasheet
| Molecular Formula | C4H6N4O3S2 |
|---|---|
| Molecular Weight | 236.3 g/mol |
| CAS Number | 554-57-4 |
| Storage Condition | Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light. |
| Solubility | >35.4 [ug/mL] (The mean of the results at pH 7.4) |
| Purity | Purity information is available upon request (COA). |
| Synonym | methazolamide; 554-57-4; Methenamide; Neptazane; Neptazaneat |
| IUPAC/Chemical Name | N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)acetamide |
| InChl Key | FLOSMHQXBMRNHR-UHFFFAOYSA-N |
| InChl Code | InChI=1S/C5H8N4O3S2/c1-3(10)7-4-9(2)8-5(13-4)14(6,11)12/h1-2H3,(H2,6,11,12) |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

